Fairfax, VANCT06332755Now EnrollingIRB Ready

Non-small Cell Lung Cancer(NSCLC) Clinical Trial in Fairfax, VA

Access cutting-edge non-small cell lung cancer(nsclc) treatment through this clinical trial at a research site in Fairfax. Study-provided care at no cost to qualified participants.

Sponsored by LG Chem

Quick Self-Assessment

See if you qualify for this Fairfax location

Preparing your pre-screening questions…

Expert Care in Fairfax

Access non-small cell lung cancer(nsclc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-small cell lung cancer(nsclc) treatment provided free

Apply for This Fairfax Location

Check if you qualify for this non-small cell lung cancer(nsclc) clinical trial in Fairfax, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fairfax

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fairfax site if eligible
  4. 4Begin participation

About This Non-small Cell Lung Cancer(NSCLC) Study in Fairfax

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.

Sponsor: LG Chem

Who Can Participate

Inclusion Criteria

Age ≥18 years old at the time of signing the ICF.
(Phase 1a only) Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1, \- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.
(Phase 1a only) Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to approved therapies, or for which the participant refuses or is ineligible for standard therapy.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
Life expectancy ≥12 weeks.
Participants with adequate organ function
No potential for childbearing or agree to use adequate contraception
Ability to understand the study purpose and procedures and have the willingness to sign a written informed consent document.
(Phase 1b only ) Must have histologically confirmed advanced or metastatic NSCLC without actionable genomic alteration that have approved therapies in the location where the participant's live and with measurable disease as determined by RECIST v1.1 Key

Exclusion Criteria

Clinically significant cardiac disease or cardiac failure.
Untreated or unstable brain or central nervous system (CNS) metastases or Leptomeningeal disease
Participants with any concurrent active malignancies
Has received prior therapy targeting LILRB or immunoglobulin-like transcript pathway.
History of life-threatening toxicity related to prior immune therapy
Has not recovered to ≤ Grade 1 or baseline from AEs and/or complications from prior surgical intervention or any anti-cancer treatment before starting study treatment
Participants must not have an active, known, or suspected autoimmune disease.
Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to initiation of study treatment therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry).
Pregnant or lactating or expecting to conceive a child during the study or within 6 months after the last dose of study intervention.
Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study intervention and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
(Phase 1b only) Participants who were previously exposed to atezolizumab

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairfax?

Yes, this clinical trial (NCT06332755) has an active research site in Fairfax, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-small Cell Lung Cancer(NSCLC) Treatment Options in Fairfax, VA

If you're searching for non-small cell lung cancer(nsclc) treatment options in Fairfax, VA, this clinical trial (NCT06332755) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairfax research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-small cell lung cancer(nsclc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-small cell lung cancer(nsclc) clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Fairfax, VA

See all lung cancer clinical trials recruiting in Fairfax — not just this study.

Browse Lung Cancer Trials in Fairfax →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Fairfax?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fairfax, VA